



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

6 May 2011
EMA/CVMP/561760/2010
Committee for Medicinal Products for Veterinary Use

Post-authorisation summary of opinion*

Metacam

International non-proprietary name (INN): Meloxicam

On 5 May 2010, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion,** recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Metacam. The marketing authorisation holder for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.

The change agreed by the CVMP concerns the addition of an indication (alleviation of pain and inflammation in acute musculo-skeletal disorders in cats) as well as additional information on the posology regarding the amounts to be administered and duration of treatment.

Detailed conditions for the use of this product will be described in the updated Summary of Product Characteristics (SPC) which will be published in the revised European Public Assessment Report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been approved by the European Commission.

* Summaries of opinion are published without prejudice to the Commission Decision.

** Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

